New York Oncology Hematology

Recent papers from New York Oncology Hematology

1. Nivolumab with doxorubicin, vinblastine, and dacarbazine in older adults with classic Hodgkin lymphoma: do S1826 results hold up in the real world?Haematologica · 2026
2. Real-world treatment patterns and outcomes in metastatic clear cell renal cell carcinoma following immune checkpoint inhibitor progression (2018-2023)The Oncologist · 2026
3. Integrated Clinicogenomic Risk Modeling for Metachronous Second Primary Cancers2026
4. Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion‐Dependent β‐ThalassemiaAmerican Journal of Hematology · 2026
5. Multimodal dynamics control activity of a glial glutamate transporter2026
6. Clinical factors driving use of RET inhibitor pralsetinib and associated real-world outcomes in RET fusion–positive NSCLC: A retrospective chart review.Journal of Clinical Oncology · 2026
7. TRIDENT: A phase 2 study of relacorilant plus nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.Journal of Clinical Oncology · 2026
8. Chemoablation with oral erdafitinib in recurrent FGFR3 -altered non–muscle-invasive bladder cancer: A phase II window-of-opportunity trial.Journal of Clinical Oncology · 2026
9. Impact of remote therapeutic monitoring on time to discontinuation and acute care events among patients treated with immune checkpoint inhibitors.Journal of Clinical Oncology · 2026
10. A URCC NCORP Research Base nationwide phase II randomized controlled trial (RCT) investigating the effect of exercise on chemotherapy-induced peripheral neurotoxicity (CIPN).Journal of Clinical Oncology · 2026
11. Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical modelsThe Journal of Experimental Medicine · 2026
12. Biomarker Testing Rates and Patterns in Patients With Metastatic Non–Small Cell Lung Cancer: A Prospective, Observational Study in Community PracticesJCO Precision Oncology · 2026
13. Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real‐world analysis from 20 US centersHemaSphere · 2026
14. Epigenetic remodeling in sarcoma promotes T-cell infiltration via modulation of the Hippo pathwayJournal for ImmunoTherapy of Cancer · 2026
15. Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK -Rearranged Squamous and Adenosquamous Non–Small Cell Lung CancersJCO Precision Oncology · 2026
16. Analysis of Clinical Benefit Using DNG64- CAR-V Chimeric Tumor Targeted Amphotropic RNA Vector in CCNG1 Expressing CancersAnticancer Research · 2026
17. Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung CancerJournal of Clinical Oncology · 2026
18. 140TiP KANDLELIT-007: Phase III, open-label study of first-line calderasib with subcutaneous pembrolizumab (pembro SC) vs pembro SC plus chemotherapy (chemo) for KRAS G12C– mutant advanced/metastatic nonsquamous NSCLCESMO Open · 2026
19. Biomarker analysis from the phase 2 LITESPARK-013 study of 2 different belzutifan (bel) doses in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC).Journal of Clinical Oncology · 2026
20. Investigating diet to control asparagine uptake as an adjunct to asparaginase treatmentFrontiers in Oncology · 2026